CCM
CMPX icon

Consonance Capital Management’s Compass Therapeutics CMPX Stock Holding History

Consonance Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,603,789
Closed -$4.22M – 3
2022
Q2 		$4.22M Sell
1,603,789
-1,896,211
-54% -$4.12M 17.79% 3
2022
Q1 		$4.74M Hold
3,500,000
– – 8.05% 5
2021
Q4 		$11.2M Buy
+3,500,000
New +$11.6M 7.28% 6

Other funds holding CMPX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

Consonance Capital Management's CMPX Position: Q3 2022 in Review

Consonance Capital Management sold out of Compass Therapeutics (CMPX) in Q3 2022, closing a stake of 1,603,789 shares — an estimated $4.22M sold.

Consonance Capital Management first reported a position in CMPX in Q4 2021 and held it in 3 quarters. The position peaked at $11.2M in Q4 2021. 38 funds tracked by Wall St. Rank hold CMPX as of Q3 2022.

  • Consonance Capital Management reported no remaining Compass Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Consonance Capital Management sold 1,603,789 Compass Therapeutics shares in Q3 2022, an estimated $4.22M.
  • Consonance Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 3 quarters.
  • Consonance Capital Management's Compass Therapeutics position peaked at $11.2M in Q4 2021.
  • 38 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2022.

Based on Consonance Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.